GSK obtains US OTC marketing rights to Mevacor from Merck
Mevacor is approved in the US for the treatment of elevated cholesterol levels that lifestyle changes alone cannot control and to reduce the risk of first heart attack,
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.